Globus Medical, Inc.
NYSE:GMEDMedical - Devices
-$2.10 today
- Market cap
- $9.34B
- Beta
- 0.95
- P/E (TTM)
- 17.4
- EPS (TTM)
- $4.33
Volume 1.43M
Average 1.45M
GMED Operating Cash Flow
Cash generated by the company's core business operations during the period.
Globus Medical, Inc.NYSE: GMED
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow growth accelerates
Q2 FY2026 operating cash flow of $209.74M rose 169.4% year over year, ahead of the +36.0% change in trailing-twelve-month operating cash flow. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +61.6% a year.
Context
- Operating cash flow amounted to 25.6% of revenue in FY2025, up 5.0 pp from a year earlier.
- Operating cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +169.4% holds above the trailing-twelve-month pace of +36.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 753.45M USD
- Year-over-year change
- +44.7%
- 4-year CAGR
- +28.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 753.45M | +44.7% |
| FY2024 | 2024-12-31 | 520.64M | +113.8% |
| FY2023 | 2023-12-31 | 243.5M | +36.4% |
| FY2022 | 2022-12-31 | 178.47M | -35.4% |
| FY2021 | 2021-12-31 | 276.27M | — |
Operating Cash Flow vs competitors
How GMED compares with its peers on the latest reported figures
- GMED's LTM Jun 2026 operating cash flow of $910.39M is the 4th largest of the 10 companies compared; the peer median is $51.56M.
- Its year-over-year change of +36.0% is the 5th highest of 10, against a peer median of +34.3%.
- Operating cash flow amounts to 28.9% of revenue for GMED, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.53B | +15.9% | +24.3% | 21.4% | |
| LTM Jun 2026 | $1.74B | +4.8% | +9.7% | 20.5% | |
| FY2025 | $1.29B | +30.2% | +40.0% | 20.8% | |
| LTM Jun 2026 | $910.39M | +36.0% | +61.6% | 28.9% | |
| LTM Mar 2026 | $102.94M | +304.2% | — | 17.9% | |
| LTM Mar 2026 | $51.56M | +558.2% | — | 6.6% | |
| LTM Mar 2026 | $34.91M | +34.3% | — | 4.2% | |
| LTM Mar 2026 | $9.15M | +288.2% | — | 7.5% | |
| LTM Mar 2026 | $3.98M | -84.0% | -39.4% | 1.6% | |
| LTM Mar 2026 | $1.87M | +119.2% | -74.7% | 0.9% | |
| Peer median (excluding GMED) | $51.56M | +34.3% | +9.7% | 7.5% | |
Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 149.19M | 190.17M | 122.87M | 102.98M | 537.87M |
| Depreciation & Amortization | 69.87M | 68.25M | 144.73M | 254.02M | 276.84M |
| Deferred Income Tax | (17.62M) | (22.22M) | (57.79M) | (125.9M) | 18.63M |
| Stock-Based Compensation | 30.59M | 32.81M | 52.74M | 54.19M | 49.78M |
| Change in Working Capital | (17.25M) | (105.26M) | (116.6M) | (97.55M) | (82.71M) |
| Accounts Receivables | (25.9M) | (50.84M) | (49.91M) | (78.06M) | (52.18M) |
| Inventory | (11.97M) | (61.75M) | (70.33M) | (29.86M) | (17.6M) |
| Accounts Payables | 3.68M | 14.42M | (14.22M) | 17.66M | 8.49M |
| Other Working Capital | 16.93M | (7.09M) | 17.87M | (7.3M) | (21.42M) |
| Other Non-Cash Items | 61.5M | 14.72M | 97.54M | 332.9M | (46.96M) |
| Operating Cash Flow | 276.27M | 178.47M | 243.5M | 520.64M | 753.45M |
| Capital Expenditures | (56.9M) | (74.05M) | (78.27M) | (115.43M) | (164.68M) |
| Acquisitions (Net) | (34.49M) | (31.44M) | (296.03M) | (17.64M) | 13.46M |
| Purchases of Investments | (622.36M) | (419.53M) | (100.64M) | (113.5M) | (107.53M) |
| Sales of Investments | 337.81M | 414.65M | 777.91M | 70.52M | 179.49M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (275.75M) |
| Investing Cash Flow | (375.94M) | (110.36M) | 302.97M | (176.05M) | (355.01M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (144.49M) | (225.56M) | (85.79M) | (300.45M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54.15M | 34.53M | (6.26M) | 58.09M | (378.71M) |
| Financing Cash Flow | 54.15M | (109.96M) | (231.82M) | (27.7M) | (679.16M) |
| Effect of Forex Changes | (810K) | (747K) | 2.18M | 255K | 22.45M |
| Net Change in Cash | (46.33M) | (42.6M) | 316.83M | 317.15M | (258.28M) |
| Free Cash Flow | 219.38M | 104.42M | 165.23M | 405.21M | 588.77M |
Globus Medical, Inc.
NYSE:GMED
Intrinsic Alpha fair value
Locked
Current Price
$70.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.